Private foundation
SAN ANTONIO, TXEIN
The funder's latest Form 990-PF says it accepts applications. Read the instructions below before you write.
Application policy: Accepts applications, as stated on the FY2024 return.
These lines count this foundation's own Form 990-PF returns that the IRS has published as data. An amended return replaces its original. They describe past returns only.
This is a count from past returns. It does not say the foundation will consider a new request. How it is counted: names are compared as written on the returns, without "The" at the start, without endings such as "Inc" or "LLC", and without spaces and punctuation. A recipient also counts as already listed when our records link it to the same organization as an earlier recipient, or when its name is almost the same as an earlier name (a trigram similarity of 0.8 or more, where 1 means identical). The state on the grant row is not compared. Grants that the foundation marked as paid to an individual, such as a scholarship, are left out of both numbers, and no count is shown when most of its grants are marked that way. A person whom the foundation did not mark as an individual is still counted as a recipient. A recipient can still look new when its name is written very differently from year to year, and two different recipients with almost the same name can be counted as one.
Application guidance comes from the funder's own Form 990-PF, Part XV (the section where a private foundation says how to apply), shown as filed. It is the funder's words, not ours. These fields are free text and the IRS form cuts them short. Filers sometimes put whole sentences in the contact-name box. Shown exactly as filed.
Giving by year
Total assets by year
| Year | Form | Revenue | Expenses | Giving | Assets | Net assets |
|---|---|---|---|---|---|---|
| FY2024 | 990-PF | $1,748,680 | $1,601,472 | $1,600,060 | $24,613,233 |
Figures are as reported on the e-filed return, with no restatement. Fiscal years are the funder's own tax year, labelled by the calendar year the period ends in. A blank line means the return does not carry that figure; a real zero shows as $0. When an amended return replaces an original, every figure here uses the amended return. The original is not shown. Giving is what the funder actually paid out toward its charitable purpose in the year (qualifying distributions on Form 990-PF, charitable disbursements otherwise). Assets are what it holds; giving is what moves.
Recipient focus areas
Where recipients are
Based on the 1% of grant rows we could match to an organization record. The rest stay as reported. The IRS assigns the NTEE category when it grants exemption. It often reflects the original filing, not today's giving.
| Recipient | Purpose | Amount | Year | Source |
|---|---|---|---|---|
| UTHSC-SA OFFICE OF THE PRESIDENTSAN ANTONIO, TX | DEVELOP NON OPIOD DRUGSTO TREAT PAIN ATTHE SOURCE | $100,000 | 2019 | |
Recipients are shown as the funder wrote them on the return. A recipient with a link was matched to an organization record; the rest stay as reported and are never guessed.
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| William C Owens Jr Trustee | TRUSTEE | 1.00 | $0 |
From the officer list on the latest e-filed return. Compensation is as reported there; a blank means the return carries no figure.
| $24,613,233 |
| FY2023 | 990-PF | $1,672,729 | $1,946,483 | $1,945,060 | $24,873,214 | $24,873,214 |
| FY2022 | 990-PF | $1,503,954 | $1,946,366 | $1,945,060 | $25,168,775 | $25,168,775 |
| FY2021 | 990-PF | $1,431,494 | $495,980 | $495,060 | $25,427,588 | $25,427,588 |
| FY2020 | 990-PF | $1,291,843 | $5,157,385 | $5,156,510 | $24,600,982 | $24,600,982 |
| FY2019 | 990-PF | $1,467,622 | $3,831,416 | $3,830,417 | $28,411,894 | $28,411,894 |
| ANALYSIS OF CANCER-ASSOCIATED MITOCHONDRIAL GENOMES TO DEVELOPNEW DIAGNOSES AND TREATMENTS |
| $100,000 |
| 2019 |
| UNIVERSITY OF CONN HEALTH CENTERFARMINGTON, CT | IODINE NANOPARTICLE-ENHANCEDRADIATION TREATMENTOF BRAIN CANCER | $100,000 | 2019 |
| UTHSC-SA OFFICE OF THE PRESIDENTSAN ANTONIO, TX | RESEARCH TUMOR-INTRINSICPD-L1 SIGNALS TO DEVELOP MEANSTO CONTROL CANCER STEM CELL FORMATION | $100,000 | 2019 |
| U T HEALTH - SAN ANTONIO (UTHSC-SA)SAN ANTONIO, TX | USE OF NOTCH INHIBITORS TOTREAT CHRONIC LYMPHOCYTIC LEUKEMIA | $100,000 | 2020 |
| U T HEALTH - SAN ANTONIO (UTHSC-SA)SAN ANTONIO, TX | POTENTIATING SYNAPSE FORMATION AS A NEWTREATMENT FOR BRAIN DISEASES, INCLUDING ALZHEIMER'S | $100,000 | 2020 |
| U OKLAHOMA HEALTH SCI CENOKLAHOMA CITY, OK | PANCREATIC CANCER TREATMENT:IMPROVING EFFECTIVENESS OF CHEMOTHERAPYBY USING SHRNA TO LOWER THE ZINC TRANSPORTER ZIP4 | $100,000 | 2021 |
| UTHSC-SA OFFICE OF THE PRESIDENTSAN ANTONIO, TX | TARGETING KYNURENINE PATHWAY ENZYMES TO REDUCE INFLAMMATION OF THE BRAIN TO TREATDEPRESSION, ALZHEIMER'S, AND OTHER BRAIN DISEASES | $100,000 | 2019 |
| U T HEALTH - SAN ANTONIO (UTHSC-SA)SAN ANTONIO, TX | DEVELOP VACCINES TO STIMULATEIMMUNE RESPONSE TO TREAT MELANOMAA VIRULENT SKIN CANCER | $100,000 | 2020 |
| UTHSC-SA OFFICE OF THE PRESIDENTSAN ANTONIO, TX | MIR-124,-128, AND -137 ASTRIGGERS OF GLIOBLASTOMA(BRAIN CANCER) DEVELOPMENT | $100,000 | 2019 |
| U OKLAHOMA FOUNDATIONNORMAN, OK | PANCREATIC CANCER RESEARCH FUND | $100,000 | 2024 |
| TEX BIOMED RES INSTITUTESAN ANTONIO, TX | TUMOR-CAUSING MUTATIONS CAUSEDBY THE IMMUNE RESPONSE TOVIRUSES WITHIN OUR DNA | $100,000 | 2020 |
| U T HEALTH - SAN ANTONIO (UTHSC-SA)SAN ANTONIO, TX | MIR-585-5P AS A NEW THERAPEUTICADJUVANT FOR TREATINGMEDULLOBLASTOMA | $100,000 | 2020 |
| UTHSC-SA OFFICE OF THE PRESIDENTSAN ANTONIO, TX | USE OF LRP1 IN THE NEURALSTEM CELL NICHE TO AIDRECOVERY AFTER A STROKE | $100,000 | 2019 |
| U T HEALTH - SAN ANTONIO (UTHSC-SA)SAN ANTONIO, TX | USE OF EWS-FLI-1 TO CHANGETUMOR MICROENVIRONMENT TO TREATEWING SARCOMA (BONE CANCER) | $100,000 | 2020 |
| UNIV OF TEXAS AT AUSTINAUSTIN, TX | APPLICATION OF PERSONALIZED MEDICINEWITH A NEW THERAPY TARGETINGGLIOBLASTOMA MULTIFORME (BRAIN CANCER TREATMENT) | $100,000 | 2020 |
| U T HEALTH - SAN ANTONIO (UTHSC-SA)SAN ANTONIO, TX | DEVELOP METHODS OF ENHANCING EFFECTIVENESS OF GLUCORTICOIDTREATMENT OF LEUKEMIA (GLUCORTICOIDS ARE SECRET OFCANCER RESISTANCE OF LONG-LIVED NAKED MOLE RAT) | $100,000 | 2020 |
| UTHSC-SA OFFICE OF THE PRESIDENTSAN ANTONIO, TX | USE OF NOTCH INHIBITORSTO TREAT CHRONICLYMPHOCYTIC LEUKEMIA | $100,000 | 2019 |
| UNIVERSITY OF HOUSTONHOUSTON, TX | KNOCK-OUT OF NUCLEAR HNRNPA2B1WITH CRISPR-CAS 9 TO ENHANCE PRODUCTIONOF ONCOLYTIC HSV IN VITRO | $100,000 | 2020 |
| UTHSC-SA OFFICE OF THE PRESIDENTSAN ANTONIO, TX | EPINGENETIC-MEDIATED ALTERNATIVE SPLICINGIN SF3B1-MUTATED CHRONIC LYMPHOCYTICLEUKEMIA PATIENTS | $100,000 | 2019 |
| U T HEALTH - SAN ANTONIO (UTHSC-SA)SAN ANTONIO, TX | DEVELOP MEANS TO PREVENTLIVER DAMAGE DURING CANCERIMMUNOTHERAPY | $99,998 | 2020 |
| U T HEALTH - SAN ANTONIO (UTHSC-SA)SAN ANTONIO, TX | EFFECTIVENESS OF COGNITIVEBEHAVIORAL THERAPY COMBINED WITH MEDICATIONSTO TREAT DEPRESSION CAUSED BY STRESS | $99,975 | 2020 |
| UTHSC-SA OFFICE OF THE PRESIDENTSAN ANTONIO, TX | DEVELOP MEANS TO PREVENTLIVER DAMAGE DURINGCANCER IMMUNOTHEARPY | $99,963 | 2019 |
| BAYLOR SCOTT & WHITE-CEN TEX FNDINTEMPLE, TX | CD44 AS A THERPEUTIC TARGET FORMETASTATIC MEDULLOBLASTOMA(BRAIN CANCER) | $99,910 | 2020 |
| U T HEALTH - SAN ANTONIO (UTHSC-SA)SAN ANTONIO, TX | TARGETED DELIVERY OF DRUGS TOREPAIR INJURED NERVES TOTREAT COGNITIVE DECLINE | $99,800 | 2020 |
Nearest by size, location and giving pattern in the database. Geography weighs heavily. Treat it as a starting list, not a ranking of fit.
Form 990-PF · FY2023 · period ending Dec 31, 2023IRS bulk XML
Filing id 202411729349101121
Form 990-PF · FY2022 · period ending Dec 31, 2022
Filing id 202333129349102503
Form 990-PF · FY2021 · period ending Dec 31, 2021
Filing id 202233129349102153
Form 990-PF · FY2020 · period ending Dec 31, 2020
Filing id 202123149349100547
Form 990-PF · FY2019 · period ending Dec 31, 2019
Filing id 202013079349101006
IRS filings are the source for every fact on this page. Nothing a model writes is ever a source; it can only point at a row here.